[Comment] Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions

In 2006, the US Food and Drug Administration (FDA) approved trastuzumab for the treatment of patients with early-stage HER2-positive breast cancer. Clinical trials have confirmed that trastuzumab-based chemotherapy significantly reduces the risk of disease recurrence and improves survival.1,2 We know that the optimal duration of treatment is 1 year, and that trastuzumab is more efficacious when administered concomitantly with chemotherapy;3 however, efforts to further improve the outcomes of these patients with new drugs have been somewhat disappointing.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research